Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertLatigo Biotherapeutics IPO Closing Marktkapitalisierung
Latigo Biotherapeutics IPO Closing Marktkapitalisierung
1,15 Mrd. $–1,3 Mrd. $ 100.0%
1,3 Mrd. $ - 1,45 Mrd. $ 1.9%
1,45 Mrd. $+ 1.9%
1 Mrd. $–1,15 Mrd. $ <1%
$1,974 Vol.
$1,974 Vol.
7. Aug. 2026
<850 Mio. $
Nein
850 Mio. $–1 Mrd. $
Nein
1 Mrd. $–1,15 Mrd. $
Nein
1,15 Mrd. $–1,3 Mrd. $
Ja
1,3 Mrd. $ - 1,45 Mrd. $
Nein
1,45 Mrd. $+
Nein
Kein Börsengang vor Oktober 2026
Nein
1,15 Mrd. $–1,3 Mrd. $ 100.0%
1,3 Mrd. $ - 1,45 Mrd. $ 1.9%
1,45 Mrd. $+ 1.9%
1 Mrd. $–1,15 Mrd. $ <1%
$1,974 Vol.
$1,974 Vol.
7. Aug. 2026
<850 Mio. $
$351 Vol.
Nein
850 Mio. $–1 Mrd. $
$436 Vol.
Nein
1 Mrd. $–1,15 Mrd. $
$193 Vol.
Nein
1,15 Mrd. $–1,3 Mrd. $
$250 Vol.
Ja
1,3 Mrd. $ - 1,45 Mrd. $
$150 Vol.
Nein
1,45 Mrd. $+
$180 Vol.
Nein
Kein Börsengang vor Oktober 2026
$414 Vol.
Nein
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Markt eröffnet: Aug 5, 2026, 5:52 AM ET
Volumen
$1,974Enddatum
7. Aug. 2026Markt eröffnet
Aug 5, 2026, 5:52 AM ETAbwickler
0x69c47De9D...Vorgeschlagenes Ergebnis: Nein
Kein Einspruch
Endgültiges Ergebnis: Nein
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$1,974Enddatum
7. Aug. 2026Markt eröffnet
Aug 5, 2026, 5:52 AM ETAbwickler
0x69c47De9D...Vorgeschlagenes Ergebnis: Nein
Kein Einspruch
Endgültiges Ergebnis: Nein
Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen